ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Budget 2023
  • Adani Saga
  • Markets
    • Stocks
    • Global Markets
    • IPO
    • Companies
    • Currency
    • Commodities
  • My Money
  • Calculators
    • Income Tax Calculator
    • Home Loan/EMI Calculator
    • Mutual Fund Returns Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • SIP calculator
    • Lumpsum Calculator
    • SWP Calculator
  • Videos
    • M Se Market
    • Jeb Zindagi Zaroorat
    • Light Camera Stocks
    • Tech Takes
    • Big Bulls Ka Nishana
    • Paisa Wasool
    • Commodity Ke MrityunjayMantra
    • The Right Property Show
  • Economy & Infra
    • Policy & Initiatives
    • Agriculture
    • Telecom
    • Aviation
    • Railways
    • Retail
    • Roadways
    • World Economy
  • Exclusive
    • Wealth Guide
    • Interviews
  • Auto
    • Cars
    • Bikes
    • Electric Vehicle
    • Commercial Vehicles
  • Tech
    • Mobiles
    • Gadgets
    • Reviews
    • Tips and Tricks
    • Apps
  • Real Estate
    • Home Buyers
    • Builders
  • Axis MF
  • Trending
    • Entertainment
    • Politics
    • Lifestyle
    • Travel
    • Sports
    • Viral
    • Education
    • Jobs
Read in App
Business News » India News

Expert tip: This Pharma stock can make you rich by giving 25% return in one year

Experts say the fundamentals of the counter are so strong that it may return to the tune of 25  per cent  within one year of the investment.

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Expert tip: This Pharma stock can make you rich by giving 25% return in one year
The counter can touch the Rs 950/stock levels in one year time. Photo: PTI

At a time when markets are nosediving and the BSE Sensex already shed over 1,000 points in one week time, Indian equity investors are looking at the indices that are still performing well. Healthcare and IT are the indices that have done reasonable well even when the markets were sliding on successive trading session. Taking cue from this, market experts have bet high on the IPCA Lab, a pharma counter. Experts say the firm may return around 25 peer cent in one year to an investor.

IPCA’s Q3 beat experts' estimates across all fronts, led by a strong pick-up in export generics and sustained growth in India formulations. While management highlighted challenges in the WHO Global Fund tender business (not received any order as yet), sluggishness in the UK business (distributor-led issue), and forex fluctuations in Russia, experts' believe strong API capabilities are core to IPCA’s diversified exports business model, which, in our view, is a major competitive advantage, given growing cost pressures in global generics. Besides, lowering dependency on the anti-malarial segment in India formulations has aided in the betterment of gross margins.

See Zee Business video below:

ज्वेलरी खरीदने की जरूरी टिप्स, जानने के लिए देखें #Valentines गिफ्ट सोना फिट या डायमंड हिट @mrituenjayj के साथ। https://t.co/3kkR4kRogB

— Zee Business (@ZeeBusiness) February 14, 2019

Speaking on the fundamentals of the counter, Bhavesh Gandhi, Analyst at Yes Securities informed Zee Business Online in a detail research report citing, "IPCA continues to report healthy numbers with Q3 growth at 10% yoy driven by branded exports, domestic sales and API traction. Branded business revenues surged 40% yoy after lackluster H1 even as management guided to steady growth. Domestic sales came in tad lower at +10% yoy though company maintained FY19 growth to come in at 14%." 

Gandhi of Yes Securities went on to add that branded growth and operating leverage tailwinds drove improved gross margin and 550bps jump in OPM; margin rise would have been higher but for remedial costs incurred for two plants and Rs 70mn penalty for failure to supply Propranolol in the US. The company remains optimistic on resumption of Global Fund business and tender allocation which would translate into better FY20 for the segment. Other parts of business notably domestic formulations and branded exports are on a steady trajectory for 10-14% growth.

On his suggestion to the market investors in regard to the IPCA Lab counter, the research report of the Yes Security attributed to Bhavesh Gandhi says, "The scrip has upside potential for 25.3 per cent and can touch Rs 950/stock levels in 12 months time." The report suggests investors take a buy position in the stock and hold it for one year. 

Standing in sync with Yes Securities views on IPCA Lab counter Sapna Jhawar, Senior Research Analysts - Pharmaceuticals at IndiaNivesh Securities said, "On the basis of strong fundamentals, the scrip is indicating an upside potential of 19 per cent. We recommend traders to buy this counter for the target of Rs 890/stock levels." The counter is currently oscillating around Rs 750 per stock levels.

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
BSE SensexNiftyMarketsIPCA Lab
Written By: Asit Manohar
Updated: Thu, Feb 14, 2019
12:13 pm
New Delhi, ZeeBiz WebDesk
RELATED NEWS
Rupee Vs Dollar: Rupee gains 8 paise to 81.80 against US dollar in afternoon trade Rupee Vs Dollar: Rupee gains 8 paise to 81.80 against US dollar in afternoon trade
Indian stock markets achieve complete transition to shorter T+1 settlement regime Indian stock markets achieve complete transition to shorter T+1 settlement regime
Hindenburg fallout? Sensex, Nifty crash as 8 of Adani Group stocks hit lower circuit; Bank Nifty sinks 1400 points: 5 key factors behind today's sell-off Hindenburg fallout? Sensex, Nifty crash as 8 of Adani Group stocks hit lower circuit; Bank Nifty sinks 1400 points: 5 key factors behind today's sell-off
Investors lose Rs 3.7 lakh crore in a day as market crashes on expiry day - key factors at play on D-Street Investors lose Rs 3.7 lakh crore in a day as market crashes on expiry day - key factors at play on D-Street
Top Gainers, Losers: Auto majors Tata Motors, Maruti help markets end in green – Check analysts' recommendation Top Gainers, Losers: Auto majors Tata Motors, Maruti help markets end in green – Check analysts' recommendation

LATEST NEWS

Magh Purnima February 2023: Date, Time, Purnima Tithi, shubh muhurat, puja rituals and significance of full moon day

Q3 Results 2023: Paytm narrows loss, IndiGo's net profit soars to Rs 1,422.6 crore

UPI-based transactions hit record 8.03 billion in January at Rs 13 trillion in value

Vedanta share price falls 5%; check dividend record date and payment date

Kamdhenu Q3 result: Net profit grows 82% to Rs 12 crore

OPPO Reno8 T 5G with curved screen, 108MP camera launched at Rs 29,999 - Check discounts, exchange offers and other details

Hyundai sold over one lakh vehicles in rural areas in 2022: HMI CEO Tarun Garg

Govt proposes changes in income tax law for startups: Here's how it will help sector to boom, top official explains

SEBI proposes to allow alternative investment funds' to carry forward unliquidated investments to new schemes

What is ASM framework in stock market and how it affects traders? Explained

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
© 2023. India Dot Com Private Limited. All Rights Reserved.
LIVE TV